TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MEDIROM Healthcare Technologies ( (MRM) ) has provided an update.
On August 22, 2025, MEDIROM Healthcare Technologies announced its involvement in the ‘World’ project, a ‘proof of human’ protocol, by installing the World ID authentication device, the ‘Orb,’ in approximately 100 Re.Ra.Ku relaxation salons. This initiative aims to provide access to a verified World ID for up to 500,000 individuals and integrate digital assets into its operations. The company plans to acquire Worldcoin tokens (WLD) and exchange up to 50% for Ethereum (ETH) as part of its financial strategy, potentially enhancing its market positioning and business expansion.
The most recent analyst rating on (MRM) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on MEDIROM Healthcare Technologies stock, see the MRM Stock Forecast page.
Spark’s Take on MRM Stock
According to Spark, TipRanks’ AI Analyst, MRM is a Neutral.
The overall stock score reflects strong technical momentum and reasonable valuation, offset by financial performance challenges. The high RSI suggests potential overbought conditions, while financial risks, particularly related to debt and cash flow, remain significant concerns.
To see Spark’s full report on MRM stock, click here.
More about MEDIROM Healthcare Technologies
MEDIROM Healthcare Technologies Inc., headquartered in Tokyo, Japan, operates a diversified healthcare business with a focus on relaxation salons under the Re.Ra.Ku brand. The company also provides health management services through its healthcare app ‘Lav’ and has ventured into the device business with the ‘MOTHER Bracelet.’
Average Trading Volume: 2,264,456
Technical Sentiment Signal: Buy
Current Market Cap: $14.22M
See more data about MRM stock on TipRanks’ Stock Analysis page.

